US Allergan goes tight with €2.7bn euro bond debut
Drug company Allergan made its debut in the euro bond market on Tuesday, bringing a multi-tranche trade that has tightened during execution despite bankers off the deal saying initial price thoughts already looked expensive.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts